Graph AI raises $3M seed to transform pharmacovigilance with AI

Graph AI, a California-based AI life sciences company focused on patient safety and pharmacovigilance, has closed a $3 million Seed funding round led by Bessemer Venture Partners. The capital will support product innovation, expansion of the engineering team, and global market adoption.

Graph AI is tackling the $8 billion pharmacovigilance market, where pharmaceutical companies monitor and report adverse drug events (ADEs) across a drug’s lifecycle to ensure patient safety and regulatory compliance. Traditional workflows rely heavily on large service firms, manual data extraction, and labor-intensive processes — often resulting in slow case processing, fragmented operations, and delayed reporting.

The company’s flagship platform, Graph Safety, uses context-aware AI and intelligent automation to streamline pharmacovigilance end-to-end. By automating ADE case processing, signal detection, aggregate reporting, and regulatory compliance, Graph Safety allows human oversight only where mandated, increasing accuracy and efficiency while maintaining regulatory standards.

Since its launch in 2024, Graph AI ...